13 Jan 2023

BioPhorum environmental sustainability roadmap 2022

Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health. The healthcare sector is responsible for 4–5% of global emissions, more than 70% of which are driven by supply chains.

The global consensus is that limiting a global temperature rise is imperative and the UN continues to encourage stakeholders, including the private sector and non-governmental organizations, to take action to reduce the impacts of climate change.

In line with this, many organizations across industry are using science-based targets for climate action to align with the 2016 Paris Agreement, which demands a clearly defined path to reduce greenhouse gas emissions. These targets require companies to work with their upstream materials suppliers and downstream distribution network and customers to reduce their total emission inventory.

This led BioPhorum members to ask for a harmonized approach across the biopharmaceutical sector to accelerate progress.

This paper is a guide for BioPhorum members and the wider biopharmaceutical industry to better understand the industry's impact on the environment while reflecting on the unique challenges that face our industry. This includes the high use of energy, water and plastics, and the carbon emissions associated with a complex global supply chain.

The paper outlines a series of high-impact opportunities for the sector to decarbonize and embed circularity across four domains: raw materials, manufacturing, distribution, and use and end of life. It collates some of the ideas and resources available to propel the biopharmaceutical industry to a more environmentally sustainable future.

Content provided by our supplier


  • GB
  • 2021
    On CPHI since
  • 100 - 249
Company types
Primary activities
Medical Devices
Regulatory Affairs
Supply Chain

Other Content from BioPhorum (10)

  • News Travel the road together toward a sustainable future

    The new BioPhorum environmental sustainability roadmap

  • Technical Data Digital Technology Roadmap

    The Digital Plant Maturity Model (DPMM)1 describes one characteristic of a Level 5: Adaptive Plant as “In-line, real-time, continuous, closed-loop, process verification and control with automated realtime quality release”. This is the pinnacle of ‘Industry 4.0’, a term coined around 2011 to outline the advantages that a wide array of digital technologies running in concert can bring to manufacturing and critical facilities. For most pharmaceutical manufacturers, the strategic advancements these technologies can deliver have not been realized.

  • Technical Data Operational vision: Adoption of in-line monitoring and real-time release

    Historically, the biopharmaceutical industry has relied on traditional pharmaceutical manufacturing practices to make and release products. This publication examines the future of biopharmaceutical manufacturing by presenting the vision of fully implemented in-line monitoring (ILM) and real-time release (RTR) (as described in BioPhorum biomanufacturing technology roadmap first edition¹).

    This aspirational vision includes full ILM, predictive analytics and advanced process controls (APC) enabling release of product in real time, with concomitant predictive and preventative alerts and resolution of process, equipment and other production issues.

  • Technical Data Current and near-future bioprocess supply situation and trends post COVID-19

    This paper provides an overview of the current and near-future bioprocess supply situation and trends. Prior to COVID-19 the bioprocess supply industry was growing at 12-14%. While some supply segments, such as single-use systems (SUS), have been growing faster than this average, overall, the bioprocessing industry pipeline continues to generate very strong demand for supplies and consumables for both COVID and non-COVID vaccines and therapies. However, recent order declines seen by suppliers have created concern. Challenges during the Pandemic created supply chain problems for biologics manufacturing that remain unresolved.
  • Video NIIMBL-BioPhorum BSB System - Buffer Preparation of the Future

    Jeff Johnson, Founder and President of Biotech Design, presents at BPI Europe July 2020 on behalf of NIIMBL and BioPhorum on the topic of Buffer Stock Blending System Buffer Preparation of the Future.
  • Podcast BioPhorum introduces - Sustainability in conversation with Cytiva

    Cytiva’s sustainability plan is a strategic intention to ensure that its policies, processes and collaborations across the value chain reflect its commitment to integrate sustainability throughout the business.

    In this podcast, Emmanuel Abate, Vice President Genomics and Cellular Research and Sustainability Executive Leader, Cytiva, talks about BioPhorum providing an excellent space to have facilitated discussions along the supply chain, allowing members to ‘lift the curtains’ on what they want to do better, and how they can do it jointly. Whilst the industry is traditionally secretive to protect IP, there are many common challenges they can work on together. One such challenge is the responsible use of single-use technology.

  • Podcast BioPhorum introduces – Sustainability in conversation with Ipsen

    Ipsen has a clear view of what it will take to deliver a 1.5-degree aligned reduction, but global availability and maturity of solutions are holding them back. 

    Colm Murphy, VP Global Environment, Health & Safety, believes Ipsen has an advantage in the fact its CEO is passionate and challenging about sustainability and this, along with the company’s size, helps when connecting corporate strategy with frontline execution.

    With one of the biggest sustainability challenges centred around supply chains, How can collaboration in BioPhorum Sustainability help to meet the targets?
  • Podcast BioPhorum introduces – A sustainable supply chain to patient

    BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies is shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.

    Lesley Holt, BioPhorum Supply Chain to Patient Director, talks about the needs and considerations of a sustainable outbound supply chain. How can your company benefit from collaboration with BioPhorum?

  • Podcast BioPhorum introduces - Sustainability in conversation with Corning

    Sustainability for many organizations is mission-critical and materials science group Corning is making great progress. Most recently, using guidance developed by the Science Based Targets initiative (SBTi) and in alignment with a 1.5°C future scenario, two more goals were added to their list of climate commitments: reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 30% (absolute basis) and relevant Scope 3 emissions by 17.5% (absolute basis) by 2028 compared to a 2021 baseline.
    In this podcast, Christie McCarthy, Director of Sustainability at Corning Life Sciences, talks about being the conductor of a sustainability orchestra, building on from pockets of goodness, connecting the dots between employees and impact, and the importance of industry engagement.
  • Webinar Developing a Sustainability Roadmap for the Biopharma Industry

    Despite broad agreement across the biopharma sector on common long-term environmental sustainability goals , there remains a lack of industry specific standards, regulations, and metrics. For the past year, BioPhorum members have collaborated across the value chain to chart a roadmap for the biopharma industry; setting out the key enablers necessary to deliver decarbonization and embed circularity. All disciplines: scientists, process engineers, procurement teams, facility designers, regulatory experts can begin to explore the vital role they play in maximizing the contribution the biopharma industry can make to repairing the planet whilst at the same time accelerating access to healthcare for all.